Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of HSK31858 in Renal Impairment
NCT07915011Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- May 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of HSK31858 in Non-cystic fibrosis bronchiectasis (NCFB) (4 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started May 2026; status: recruiting.
02
Drugs
HSK31858
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT07915011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07915011.